Predictive utility of remnant cholesterol in atherosclerotic cardiovascular disease
- PMID: 38456429
- DOI: 10.1097/HCO.0000000000001140
Predictive utility of remnant cholesterol in atherosclerotic cardiovascular disease
Abstract
Purpose of review: Remnant cholesterol (RC) is the cholesterol carried in lipoproteins derived from the catabolism of chylomicrons and very low-density lipoproteins. Evidence supporting the causal relationship of RC with atherosclerotic cardiovascular disease (ASVD) is accumulating rapidly. The number of impactful contributions to this field are increasing and provide a pathophysiological insight into the current residual cardiovascular risk beyond low-density cholesterol (LDL)-cholesterol (LDL-C). They also raise the question of whether RC should be used in prediction models and become the target of new therapeutic interventions. The intent of this review is to highlight the recent advances on the role of RC in atherogenesis and the validation of RC as a predictor of ASVD.
Recent findings: Numerous prospective and retrospective cohorts helped validate a significant causal relationship of RC with various forms of ASVD, independent of LDL-C. A recent large Mendelian randomization study reinforced the existence of this relationship and showed that the risk of atherosclerotic events was driven nearly entirely by a direct effect of RC.
Summary: Both available and accumulating evidence suggest that a lifelong reduction in RC could translate into a substantial reduction in ASVD risk. The data support a revision of current guidelines to incorporate RC as an independent risk factor for ASVD. We propose that early screening of RC should be implemented and that RC lowering should become the target of future drug developments.
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
References
-
- Canada PHAo. Heart disease in Canada: Gouvernement du Canada; 2022 [updated July 28, 2022]. Available at: https://www.canada.ca/en/public-health/services/publications/diseases-co... .
-
- Evaluation IfHMa. Cardiovascular diseases – level 2 cause. Available at: https://www.healthdata.org/results/gbd_summaries/2019/cardiovascular-dis... .
-
- Davidson MH. Reducing residual risk for patients on statin therapy: the potential role of combination therapy. Am J Cardiol 2005; 96 (9A):3K–13K. discussion 34K–35K.
-
- Residual Risk Reduction Initiative. Available at: https://www.r3i.org/ .
-
- Varbo A, Benn M, Nordestgaard BG. Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. Pharmacol Ther 2014; 141:358–367.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
